bluebird (BLUE) Underperforms Industry YTD Amid Challenges

bluebird bio’s (BLUE) shares have lost 25.4% year to date compared with the industry’s decline of 7.9%.As of now, the going is challenging for bluebird. While the approval of its three gene therapies bodes well, the uptake of the same has not gained traction as expected.Image Source: Zacks Investment ResearchThe FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusion on Aug 17, 2022. It also approved Skysona for treating early, ...